RT Journal Article
SR Electronic
T1 Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.11.20147793
DO 10.1101/2020.07.11.20147793
A1 Clayton B. Hess
A1 Zachary S. Buchwald
A1 William Stokes
A1 Tahseen H. Nasti
A1 Jeffrey M. Switchenko
A1 Brent D. Weinberg
A1 Nadine Rouphael
A1 James P. Steinberg
A1 Karen D. Godette
A1 David Murphy
A1 Rafi Ahmed
A1 Walter J. Curran, Jr
A1 Mohammad K. Khan
YR 2020
UL http://medrxiv.org/content/early/2020/07/14/2020.07.11.20147793.abstract
AB Background Safety of whole-lung low-dose radiation therapy (LD-RT) for COVID-19 pneumonia has been established in two phase I trials. By focally dampening pulmonary cytokine hyperactivation, LD-RT may improve outcomes in hospitalized and oxygen-dependent COVID-19 patients.Methods Patients with COVID-19 pneumonia were treated with 1.5 Gy whole-lung LD-RT, followed for 28 days or at least until hospital discharge, and compared to an age- and comorbidity-matched control cohort. COVID-19-positive patients eligible for this protocol were hospitalized, had radiographic consolidations, and required supplemental oxygen. Efficacy endpoints were time to clinical recovery, radiographic improvement, and serologic responses.Results Ten patients received whole-lung LD-RT between April 24 and May 24, 2020 and were compared to ten matched control patients, of whom six received COVID-directed therapy. Median time to clinical recovery was 12 days for the control cohort vs 3 days for LD-RT (HR 2.9, p=0.05). Median time to hospital discharge (20 and 12 days, p=0.19), and intubation rates (40% and 10%, p=0.12) were shorter for the LD-RT cohort. The LD-RT cohort had faster radiographic improvement (p=0.03), even among patients with high COVID burden. Serologic recovery in specific hematologic, cardiac, hepatic, clotting, and inflammatory markers occurred more rapidly following LD-RT than among matched controls.Conclusions Strong efficacy signals, including a 3-fold risk reduction in time to clinical improvement, were observed following LD-RT compared to matched patients receiving COVID-directed therapy for COVID-19 pneumonia. Given the global availability of radiation accelerators, ongoing international efforts to investigate the optimal role of LD-RT in COVID-19 pneumonia are justified.Clinical Trial Registration NCT04366791.Competing Interest StatementProvisional Patent Applied.Clinical TrialNCT04366791Funding StatementThis trial was not funded by any external entity. Investigators self supported this trial by volunteering their own times and efforts.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Emory IRB approved the trial.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data and results are included in the manuscript.